Phaseline

Targets › KLK3

KLK3 (Prostate-specific antigen): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Oct 2027.

Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum. (UniProt, P07288)

Open in Phaseline: the race on KLK3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1
CEA, BRACHYURY, MUC1, KLK3, TBXTPhase 2Adenocarcinoma; Metastatic Colorectal CancerOct 2027
Radiopharm Theranostics161Tb-RAD402
Radiolabeled anti-KLK3 monoclonal antibody targeting free prostate-specific antigen
KLK3Phase 1Castration-resistant Prostate CancerNov 2028

Conditions

Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Castration-resistant Prostate Cancer (1)

Modalities

mixed (1), small molecule (1)

Companies

National Cancer Institute (NCI) (1) Radiopharm Theranostics (1)

Related targets

CEA (1) BRACHYURY (1) MUC1 (1) TBXT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.